These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32162475)

  • 1. Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-1
    Tarbe M; Miles JJ; Edwards ESJ; Miles KM; Sewell AK; Baker BM; Quideau S
    ChemMedChem; 2020 May; 15(9):799-807. PubMed ID: 32162475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition.
    Douat-Casassus C; Borbulevych O; Tarbe M; Gervois N; Jotereau F; Baker BM; Quideau S
    J Med Chem; 2010 Oct; 53(19):7061-6. PubMed ID: 20806940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
    Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
    Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.
    Borbulevych OY; Santhanagopolan SM; Hossain M; Baker BM
    J Immunol; 2011 Sep; 187(5):2453-63. PubMed ID: 21795600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.
    Maeurer MJ; Necker A; Salter RD; Castelli C; Höhn H; Karbach J; Freitag K; Neukirch C; Knuth A; Jäger E
    Int J Cancer; 2002 Jan; 97(1):64-71. PubMed ID: 11774245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
    Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
    J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
    Douat-Casassus C; Marchand-Geneste N; Diez E; Gervois N; Jotereau F; Quideau S
    J Med Chem; 2007 Apr; 50(7):1598-609. PubMed ID: 17328535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
    Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
    Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.
    D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P
    Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive T cell receptor cross-reactivity on structurally diverse haptenated peptides presented by HLA-A2.
    Gagnon SJ; Turner RV; Shiue MG; Damirjian M; Biddison WE
    Mol Immunol; 2006 Feb; 43(4):346-56. PubMed ID: 16310048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.
    Meng Z; Wang Y; Zhang G; Ke Y; Yan Y; Wu L; Huang Q; Zeng G; Wang Y; Ying H; Jiao S
    J Immunother; 2011 Sep; 34(7):525-34. PubMed ID: 21760531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
    Baumgaertner P; Schmidt J; Costa-Nunes CM; Bordry N; Guillaume P; Luescher I; Speiser DE; Rufer N; Hebeisen M
    Front Immunol; 2022; 13():973986. PubMed ID: 36032094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.
    Fleischhauer K; Tanzarella S; Wallny HJ; Bordignon C; Traversari C
    J Immunol; 1996 Jul; 157(2):787-97. PubMed ID: 8752930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtle changes at the variable domain interface of the T-cell receptor can strongly increase affinity.
    Sharma P; Kranz DM
    J Biol Chem; 2018 Feb; 293(5):1820-1834. PubMed ID: 29229779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational design of the affinity and specificity of a therapeutic T cell receptor.
    Pierce BG; Hellman LM; Hossain M; Singh NK; Vander Kooi CW; Weng Z; Baker BM
    PLoS Comput Biol; 2014 Feb; 10(2):e1003478. PubMed ID: 24550723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.